TheraCryf PLC
8EV
Company Profile
Business description
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
stocks
AMD earnings: Data center demand still looks quite strong to us
AMD has the components to target $100 billion of AI revenue in the next few years.
stocks
PayPal earnings: Growth slows, new CEO appointed
We expect to lower our fair value estimate of PayPal stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,154.90 | 49.70 | -0.54% |
| CAC 40 | 8,275.77 | 13.61 | 0.16% |
| DAX 40 | 24,530.19 | 72.85 | -0.30% |
| Dow JONES (US) | 49,278.32 | 37.33 | 0.08% |
| FTSE 100 | 10,363.92 | 38.42 | -0.37% |
| HKSE | 26,885.24 | 37.92 | 0.14% |
| NASDAQ | 22,904.58 | 350.61 | -1.51% |
| Nikkei 225 | 53,818.04 | 475.32 | -0.88% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,848.62 | 69.19 | -1.00% |
| S&P/ASX 200 | 8,889.20 | 38.60 | -0.43% |
| SSE Composite Index | 4,075.92 | 26.29 | -0.64% |